Inflammatory Bowel Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with IBD (Crohn's Disease, Ulcerative Colitis or Unclassified Colitis) of mild to moderate intensity; age equal to or greater than 18 years and up to 80 years; Patients using conventional drug therapy for IBD (aminosalicylates, immunosuppressants, biological); Function preserved kidney and liver
Exclusion criteria
Exclusion criteria: Pregnancy; Change or withdrawal of dosage/conventional medication for IBD; HIV positive patients and compromised renal and hepatic function; Patients who made inadequate use of supplementation (did not ingest the recommended daily dose)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1 - It is expected to find improved antioxidant activity (reduction of lipid peroxidation - malonaldehyde levels (MDA) and oxidized glutathione (GSSG) - increased antioxidant activity - superoxide dismutase (SOD), reduced glutathione (GSH), and reduced inflammatory activity (tumor necrosis factor alpha (TNF?) and interleukins (IL));Outcome found 1 - It was noticed that there were no changes in the inflammatory profile (fecal calprotectin, TNFa and IL) after supplementation with curcumin and curcumin+piperine. Regarding oxidative stress, the group supplemented with curcumin+piperine had an increase in SOD activity (p<0.05) compared to the placebo group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2 - It was expected to find improvement in gastrointestinal complaints, such as nausea, vomiting, diarrhea, constipation, etc. | — |
Countries
Brazil
Contacts
Universidade Federal de Alagoas